Indian pharmaceutical companies are making their first forays in the biotechnology arena, helping the market expand from a standing start at the beginning of the decade to reach a value of $2bn in 2006-7, according to a recent report from KPMG.
China is the ideal destination for outsourcing, according to a report by PricewaterhouseCoopers (PwC) that has calculated rankings based on a range of parameters.
Ion channel expert ChanTest is expanding its range of ion channel services and cell lines that help identify promising target compounds and those that could cause harmful side effects.
Phylogeny has launched the first microRNA (miRNA) in situ hybridisation detection service to help scientists delve deeper into the mechanisms controlling key biological processes.
UK-based Pharmaceutical Profiles has used an imaging technique known as scintigraphy to quantify the effects of Amylin / Eli Lilly’s latest diabetes drug on the stomach.
Charles River Laboratories has agreed to buy US-based drug discovery imaging expert Molecular Imaging Research, Inc. (MIR) for approximately $12.5m (€8.8m) in cash.
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
Assay Depot, a new online marketplace which allows bench researchers around the world to choose and buy a broad range of drug discovery services, went live yesterday.
BioReliance has had to significantly expand its Rockville, US, facility and hire new staff in order to accommodate the growing demand for its genetic toxicology (GeneTox) testing services.
Drug discovery informatics and services provider, Tripos International, has agreed to buy Pharsight Corporation, a provider of software and strategic services for clinical drug development.
UK analytical services expert, Quotient Bioscience has received a significant equity investment from TA Associates to help further the firm’s acquisition-led and organic growth strategy.
Caliper Life Sciences has launched two new kinase profiling services as well as new assay kits that aim to provide researchers with a better understanding of their kinase inhibitor drug candidates.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
UK laboratory services firm LGC has brought the first BioMark system into the UK in order to accurately quantify rare gene sequences for its pharmaceutical customers.
Galapagos has bolstered the portfolio of its BioFocus DPI contract services unit by purchasing the structure-based drug discovery business of UK firm Sareum.
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
Charles River Laboratories saw its operating income advance 16 per cent to $77m in the second quarter on strong demand for its research services division, and also announced a $53m deal to buy a German contract service organisation.
Eli Lilly took a giant leap down the outsourcing road yesterday with the sale of a major R&D facility to contract research organisation Covance and the forging of additional agreement with Quintiles and i3.
US contract research giant Covance saw a strong performance across its divisions in the second quarter that lifted its revenues by 15 per cent to $462m.
Pharmaceutical Product Development (PPD) reported a bumper set of second quarter figures, well ahead of analysts expectations, but saw its share price take a dip anyway.
The estimated 15 year period, $800m (€509) investment and one in 5,000 chance of successfully developing a new drug is likely to see more and more pharmaceutical firms partner with CROs in a bid to offset risk, according to a report Turner Investment...
Outsourcing-Pharma.com presents its periodic round-up of personnel changes in the pharmaceutical outsourcing arena, with senior appointments at Bristol-Myers Squibb, Parexel and GVK Bio, amongst others.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
MDS Analytical Technologies has followed its acquisition of
Molecular Devices last year by snapping up high content screening
(HCS) experts Blueshift for $15m (€9.45m).
Immtech Pharmaceuticals has become the latest in a string of
western research and development services firms to announce a
partnership with a peer in China in a bid to get a foothold in this
market of vast potential.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving PPD, PRA
International, SpineMark and Pacific Biometrics.
Commonwealth Biotechnologies (CBI) has planted its first roots in
Japan, as the world's number two pharmaceutical market continues to
attract foreign firms.
Singapore's Economic Development Board has been taking strides over
the past year to further its biomedical sciences industry and vie
for global attention amidst the other Asia Pacific players,
particularly in the field of translational...
China's Wuxi PharmaTech saw revenues race away across its divisions
in the first quarter of 2008, benefitting from the continued shift
towards outsourcing of manufacturing and laboratory functions by
the pharmaceutical industry.
Canada has bought its laboratory legislation in line with other
international standards as the country proposes new legislation
designed to tighten safety and access to human pathogens and
toxins.
Quotient BioResearch has consolidated its three latest drug
development acquisitions under a united front and the hungry firm
is now on the hunt for further purchases.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving Tigermed Consulting,
Lifetree Clinical Research, Synexus and Anapharm.
Continued weakness in the market for products used in the
manufacture of biologic drugs was the main reason why Millipore
experienced a 'challenging' quarter, according to CEO Martin
Madaus.
US-based BioDuro and The National Center for Safety Evaluation of
Drugs (NCSED) in Beijing have received full accreditation from the
Association for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC).
In this week's review of activity within the preclinical research
services arena, news has emerged involving MIR Preclinical
Services, Commonwealth Biotechnologies and Innogenetics.
Three Indian contract research organisations (CROs) - Asian
Clinical Trials (ACT), Veeda Clinical Research and Siro Clinpharm
have made recent global moves in order to add more muscle to their
industry presence.
Overall, 2007 was another stellar year for contract service
providers, particularly those at the early-stage end of
development, although companies are advised to watch out for a
tougher environment ahead.
Genomic services firm Expression Analysis has purchased the
first-ever commercially-available technology to allow the
sequencing of a single molecule of DNA, without amplification.
Applied Biosystems has sequenced a human genome for just $60,000 in
a project that significantly undercuts the $100,000 milestone
achieved by the industry and setting the scene for a price war
between DNA sequencing tool specialists.
Eli Lilly has again teamed up with Indian research firm Suven Life
Sciences in a deal that will focus on preclinical research of
molecules in the therapeutic area of central nervous system (CNS)
disorders.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
The use of internal standards (IS) is essential for developing and applying liquid chromatography-tandem mass spectrometric (LC-MS/MS) quantitative bioanalytical...
Global regulatory standards govern bioanalytical method development, validation and the subsequent assays. When those standards are updated, industry stakeholders...
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...
